Evidence map›Paper›PMID 38135789›Full record

SynthesisArchives of orthopaedic and trauma surgery2024

The effect of teriparatide on patients with atypical femur fractures: a systematic review and meta-analysis.

Hazem Mohamed Salamah, Khaled Alsayed Abualkhair, Sara K Kamal, Hazem A Mohamed, Ahmad Alkheder, Mohamad Ali Farho, Dillan Mistry, Hany Elbardesy

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Archives of orthopaedic and trauma surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Hazem Mohamed SalamahFaculty of Medicine, Zagazig University, Zagazig, 44519, Egypt. hazem.salamah@gmail.com.ORCID http://orcid.org/0000-0002-2291-8862
Khaled Alsayed AbualkhairFaculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Sara K KamalFaculty of Medicine, Cairo University, Cairo, Egypt.
Hazem A MohamedFaculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Ahmad AlkhederDepartment of Otorhinolaryngology, Al Mouwasat University Hospital, Faculty of Medicine, Damascus University, Damascus, Syria.
Mohamad Ali FarhoFaculty of Medicine, University of Aleppo, Aleppo, Syria.
Dillan MistryDepartment of Orthopaedics Mid Yorkshire Hospitals, Leeds, UK.
Hany ElbardesyDepartment of Trauma and Orthopaedics, Liverpool University Hospitals, Liverpool, UK.
Zagazig University · EGCairo University · EGMid Yorkshire Hospitals NHS Trust · GBSyrian Private University · SYUniversity of Aleppo · SYUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBisphosphonates (BPs) are one of the most often used drugs to lower fracture risk in osteoporosis patients; nonetheless, BPs have been linked to atypical femoral fracture (AFF). Teriparatide (TPTD) is a parathyroid hormone analogue and anabolic drug that may accelerate fracture repair. TPTD has been considered as a possible treatment for AFF, particularly those caused by BP use. We evaluate the effect of TPTD on AFF in this systematic review and meta-analysis. MATERIALS AND

methodsA thorough search of: Web of Science, Scopus, PubMed, and Cochrane was conducted on August 2, 2023. Trials evaluating the effect of TPTD on the incidence of: complete bone healing, non-union, early and delayed bone union, progression of incomplete AFF to complete AFF, and time to bone union were included. Using Review Manager (RevMan) version 5.4, the risk ratio (RR) and mean difference (MD) with the corresponding 95% confidence interval (CI) were estimated for dichotomous and continuous outcomes, respectively. The Newcastle-Ottawa Scale was used to assess the quality of studies.

resultsEight studies met the eligibility criteria and were included in our analysis. TPTD significantly increased the incidence of early bone union (RR = 1.45, 95% CI [1.13, 1.87], P = 0.004) and time to bone union (MD = -1.56, 95% CI [-2.86, -0.26], P = 0.02) compared to the control group. No significant differences were observed in terms of complete bone healing (RR = 1.09, 95% CI [0.99, 1.13], P = 0.12), non-union (RR = 0.48, 95% CI [0.22, 1.04], P = 0.06), and progression of incomplete AFF to complete AFF (RR = 0.27, 95% CI [0.04, 1.97], P = 0.19).

conclusionsTPTD is an effective therapy for enhancing and hastening healing following AFF, particularly in postoperative settings. Future large randomized clinical trials are needed to confirm or dispute the results.

Indexed as

Bone Density Conservation AgentsFemoral FracturesFracture HealingTeriparatideHumansBone Density Conservation AgentsTeriparatideAFFAtypical femoral fractureBone unionFracture healingTeriparatideTPTD

Identifiers

PMID38135789
PMCPMC10896930
OpenAlexW4390101096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.